Radiation syndrome treatment market to reach $8,256 Million by 2024
Radiation Toxicity Treatment Market Outlook To 2024: Key Exposure Type (Acute Radiation Syndrome, Chronic Radiation Syndrome), Radiation-Type (Ionizing, Non-Ionizing), Disease Type, Treatment Type, Regional Segmentation, Pipeline Analysis, Regulatory Landscape, Competitive Dynamics, M&A Insights, Segment Forecast And Conclusion
7th October 2017, Florida- The Global Radiation Toxicity Treatment market size will be worth USD 8.25 billion by 2024, according to a new research study published by Ameri Research. The factors driving the market growth include Increasing use of radiation therapy, Nuclear medicine in the treatment and diagnosis of diseases and Increasing Government Support for Research and Development.
Rising tension and missile warfare at Korean peninsula putting the world at a crossroad of possible dangerous nuclear disaster. A 10-kiloton detonation to city population like Virginia (with a population of 2 million) can bring more than 270,000 Acute Radiation Syndrome incidents. Hence major federal governments of the world are keeping them prepared for the treatment.
Some of the leading players in the market have been assessed using three major parameters such as Product portfolio, Government funding and Market Dominance. In addition, few other parameters considered include financials, technological advancements and product reviews from end users. Among the companies evaluated, Aeolus Pharmaceutical promised to be a significant player. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (“Lung-ARS”) under a $118MM, 5-year contract from the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services. Their range of products developed has application from Acute Radiation Syndrome to Nerve gas exposure.
U.S being the largest market because of its sensitive military activities and threat perception. It accounted for xx % of the market share in 2016 ($ x,xxx Million) and will keep growing to occupy 54% of the global market. Middle East market in decline trend due to moving out of U.S troops and reducing threat perception. In Europe, UK, Germany, France represent significant market.
Click the link below to view the report description: – https://www.ameriresearch.com/product/radiation-toxicity-treatment-market-size/
Key findings from the study:-
- The global radiation syndrome treatment market is worth $ 4,655 Million in 2016 and expected to be $ 8,256 Million by 2024 growing at a CAGR of 6.57%.
- In Asia, Japan and Korea are the markets with huge demand for the Acute Radiation Syndrome treatment modalities. Aeolus also has collaboration with Israel, Japan, and South Korea governments to supply their biodefense products. Their product AEOL-10150 has emergency use authorization prior FDA approval. Onconova Therapeutics’ Recilisib is a product candidate being developed in collaboration with the U.S. Department of Defense for acute radiation syndromes.
- key market players include Osiris Therapeutics Inc., Nanotherapeutics Inc., NeoStem Inc., Gamida Cell Ltd, Cantex Pharmaceuticals Inc., Aeolus Pharmaceuticals, Cleveland BioLabs Inc., Tonix Pharmaceuticals Holding Corp, Onconova Therapeutics Inc.
Ameri Research has segmented the Radiation Toxicity Treatment Market by product, application, and region:
Radiation Toxicity Treatment Market by “Type of Exposure” (Revenue, USD Million, 2014- 2024)
- Acute radiation syndrome (ARS) (Single large exposure)
- Chronic Radiation Syndrome (Small exposures spread over time)
Radiation Toxicity Treatment Market by “Radiation Type” (Revenue, USD Million, 20124- 2024)
- Ionizing (Alpha/Beta/Gama)
Radiation Toxicity Treatment Market by “Disease Type” (USD Million) (Revenue, USD Million, 20124- 2024)
- Bone Marrow Syndrome (Hematopoietic)
- Gastrointestinal Syndrome (GI)
- Cardiovascular (CV)
- Central Nervous System (CNS) Syndrome
Radiation Toxicity Treatment Market Regional Outlook (Revenue, USD Million, 20124- 2024)
- North America
- Latin America
- Asia pacific
- Middle East & Africa
- Saudi Arabia
- South Africa